Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

Press/Media

Period10 Dec 2022 → 11 Dec 2022

Media coverage

84

Media coverage